|
|
 |
|
Viewing report
|
|
|
|
Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017
GlobalData, May 2011, Pages: 78
Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017”. The report is an essential source of information and analysis on the global thyroid cancer therapeutics market. The report identifies the key trends shaping and driving the global thyroid cancer therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to sithyroid cancerificantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global thyroid cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimated that the thyroid cancer market was worth $55m in 2010. The major reason for the limited market revenues was the lack of approved drugs for the treatment of thyroid cancer. Thyroid cancer is mainly treated by surgery and radiotherapy. Chemotherapy has fewer roles to play in the treatment. Mainly doxorubicin is used as an off-label drug for treating the patients with anaplastic thyroid cancer; also some other off-label drugs such as cisplatin and carboplatin are used, but they have lower response rates. The high growth forecast for the thyroid cancer therapeutics market is primarily attributed to a strong pipeline. The upcoming four pipeline molecules (Pre-registration (1) and Phase III (3)) in the next seven years will take a steep rise in the market. Overall, between 2010 and 2017, the thyroid cancer market is expected to grow at a CAGR (Compound Annual Growth Rate) of 27.34% to reach $298m by 2017.
Scope
The report provides information on the key drivers and challenges of the thyroid cancer therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) thyroid cancer therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as Tyrosine Kinase Inhibitor, VEGFR Inhibitors, Multi kinase inhibitors, vascular disrupting agents, Topoisomerase inhibitor, Potent deacetylase inhibitor, Serine/threonine-protein kinase, liposomal FAK, Antifolate, SYK Inhibitor, mTOR Inhibitor, Peroxisome proliferator-activated receptor gamma agonist, Multi kinase angiostenin inhibitor, BRAF Kinase inhibitor.
- Analysis of the current and future competition in the seven key countries thyroid cancer therapeutics market. Key market players covered Bayer, Oynx Pharmaceutical, AstraZeneca PLC, Oxigene Inc, Exelixis Inc., Novartis AG, Pfizer, Eisai Co., Daichii SankyoLtd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the thyroid cancer therapeutics market.
- Analysis of key recent licensing and partnership agreements in thyroid cancer therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and desithyroid cancer your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global thyroid cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global thyroid cancer therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global thyroid cancer therapeutics market landscape? – Identify, understand and capitalize.
|
|
|
|
